ATE399567T1 - Peg konjugate von lhrh analogen - Google Patents

Peg konjugate von lhrh analogen

Info

Publication number
ATE399567T1
ATE399567T1 AT05012776T AT05012776T ATE399567T1 AT E399567 T1 ATE399567 T1 AT E399567T1 AT 05012776 T AT05012776 T AT 05012776T AT 05012776 T AT05012776 T AT 05012776T AT E399567 T1 ATE399567 T1 AT E399567T1
Authority
AT
Austria
Prior art keywords
peg conjugates
lhrh analogue
conjugates
lhrh analog
peg
Prior art date
Application number
AT05012776T
Other languages
English (en)
Inventor
Tayar Nabil El
Xuan Zhao
Michael D Bentley
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE399567T1 publication Critical patent/ATE399567T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05012776T 1998-04-28 1999-04-28 Peg konjugate von lhrh analogen ATE399567T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8334098P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
ATE399567T1 true ATE399567T1 (de) 2008-07-15

Family

ID=22177691

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05012776T ATE399567T1 (de) 1998-04-28 1999-04-28 Peg konjugate von lhrh analogen
AT99921497T ATE297762T1 (de) 1998-04-28 1999-04-28 Peg-lhrh analog konjugate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99921497T ATE297762T1 (de) 1998-04-28 1999-04-28 Peg-lhrh analog konjugate

Country Status (12)

Country Link
US (2) US6433135B1 (de)
EP (1) EP1075282B1 (de)
JP (1) JP2002512982A (de)
AT (2) ATE399567T1 (de)
AU (1) AU760381B2 (de)
CA (1) CA2330448A1 (de)
DE (2) DE69939036D1 (de)
DK (1) DK1075282T3 (de)
ES (2) ES2309618T3 (de)
IL (2) IL139285A0 (de)
PT (1) PT1075282E (de)
WO (1) WO1999055376A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4011124B2 (ja) * 1997-06-06 2007-11-21 協和醗酵工業株式会社 化学修飾ポリペプチド
MEP42108A (en) * 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
JP2002534363A (ja) * 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
MXPA02003176A (es) * 1999-10-04 2002-09-30 Shearwater Corp Neuropeptidos estabilizados por polimero.
PE20020376A1 (es) * 2000-09-29 2002-05-13 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
AU2003303714B2 (en) 2003-01-13 2009-02-19 Bracco Imaging S.P.A. Improved linkers for radiopharmaceutical compounds
NZ542094A (en) * 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
JP2007523630A (ja) 2003-05-09 2007-08-23 ネオス テクノロジーズ インコーポレイテッド ヒト成長ホルモングリコシル化突然変異体の組成と調合法
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
BRPI0519430A2 (pt) * 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US8012488B2 (en) * 2005-02-18 2011-09-06 Nof Corporation Polyoxyalkylene derivative
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (de) 2005-05-25 2016-01-20 Novo Nordisk A/S Glykopegylierter Faktor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2049144B8 (de) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20090149673A1 (en) * 2007-12-05 2009-06-11 Semprus Biosciences Corp. Synthetic non-fouling amino acids
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
EA201492269A1 (ru) 2012-06-04 2016-02-29 Опко Байолоджикс Лтд. Пегилированные варианты oxm
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
JPH03148298A (ja) * 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7953788B2 (en) * 2001-09-29 2011-05-31 Siebel Systems, Inc. System and method for queuing data for an application server

Also Published As

Publication number Publication date
US7268210B2 (en) 2007-09-11
IL139285A (en) 2007-03-08
AU760381B2 (en) 2003-05-15
DK1075282T3 (da) 2005-10-10
ATE297762T1 (de) 2005-07-15
ES2309618T3 (es) 2008-12-16
ES2242396T3 (es) 2005-11-01
CA2330448A1 (en) 1999-11-04
IL139285A0 (en) 2001-11-25
DE69939036D1 (de) 2008-08-14
AU3869699A (en) 1999-11-16
US6433135B1 (en) 2002-08-13
JP2002512982A (ja) 2002-05-08
DE69925830D1 (de) 2005-07-21
PT1075282E (pt) 2005-09-30
US20050222214A1 (en) 2005-10-06
EP1075282A1 (de) 2001-02-14
EP1075282B1 (de) 2005-06-15
DE69925830T2 (de) 2006-05-04
WO1999055376A1 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
ATE399567T1 (de) Peg konjugate von lhrh analogen
FI963103A0 (fi) Ei-virusvektori
DK0909183T3 (da) DHA-konjugerede farmaceutisk midler
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
AP2001002187A0 (en) Piperidines as CCR5 modulators.
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
BG104871A (bg) Полиол - интерферон - бета конюгати
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
BE2013C033I2 (de)
GEP20053473B (en) High Potency Dihydroergotamine Compositions
DE69733272D1 (de) N-(aryl/heteroarylacetyl)aminosäureester, diese enthaltende pharmazeutische zusammensetzungen und methoden zur inhibierung der beta-amyloidfreisetzung und/oder deren synthese unter verwendung dieser verbindungen
EA199700151A1 (ru) Композиция для чрескожного введения
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
LU91281I2 (fr) Preotact-hormone parathyroïde
DE69033970D1 (de) Huperzin a analoge verbindungen
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
BG105275A (en) Tan-1057 derivatives
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
NO995481L (no) Glykokonjugater av 20 (S)-camptothecin
EA200100674A1 (ru) Клатраты дегидроэпиандростерона и соответствующие фармацевтические композиции
ATE203665T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
DE59802925D1 (de) Verfahren zum herstellen von extrakt enthaltenden pharmazeutischen formulierungen
ATE519502T1 (de) Kohlenhydratkonjugate zur verhinderung des missbrauchs kontrollierter substanzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties